Solid and Hematological Malignancies
0
Pipeline Programs
4
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Cell Therapy
267%
Small Molecule
133%
+ 1 programs with unclassified modality
Competitive Landscape
4 companies ranked by most advanced pipeline stage
Adaptimmune TherapeuticsPA - Philadelphia
1 programGenetically engineered T Cell ReceptorsN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Kite PharmaAxicabtagene Ciloleucel
Adaptimmune TherapeuticsGenetically engineered T Cell Receptors
Clinical Trials (2)
Total enrollment: 1,002 patients across 2 trials
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
Start: Dec 2021Est. completion: Dec 20401,000 patients
N/AEnrolling By Invitation
Long Term Follow up of Subjects Exposed to Genetically Engineered T Cell Receptors
Start: Feb 2018Est. completion: Jul 20182 patients
N/ATerminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
Cell Therapy is the dominant modality (67% of programs)
4 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.